Heat Biologics (HTBX) Stock Is Flying On COVID-19 News

Heat Biologics HTBX Stock News

Heat Biologics Inc (NASDAQ: HTBX) is making a run for the top in the market this morning, and for good reason. The company announced a coronavirus-related collaboration, exctng investors. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HTBX Stock Soars On Coronavirus Collaboraton

In the press release, Heat Bologics said that t entered into a collaboraton with Waisman Biomanufacturing. The collaboraton surrounds the establishment of a partnership to manufacture the company’s COVID-19 vaccine candidate.

Importantly, Waisman specializes in the manufacture of cellular therapeutics and other biologics for early-stage clinical trials and is part of the University of Wisconsin. To date, it has manufactured more than 320 clinical grade products. Moreover, the company has earned a reputation for cost-effective and timely production.

HTBX and Waisman have a history. In fact, Waisman is key in manufacturing the company’s HS-130 candidate, a candidate that is currently in Phase 1 clinical trials.

In the release, the company reminded investors that its vaccine candidate leverages its proprietary gp96 platform to target the SARS-CoV-2 coronavirus that causes COVID-19.

In a statement, Jeff Wolf, CEO at HTBX, had the following to offer:

We continue to advance our COVID-19 vaccine and are pleased to be working with Waisman to assist our manufacturing efforts. We remain encouraged by the potential of our platform to provide broad protection against COVID-19, particularly for elderly patients and those with underlying health conditions that have an increased risk of complications and death from COVID-19. Our confidence is reinforced by numerous National Institutes of Health (NIH) and U.S. Department of Defense (DOD)-funded mice and primate trials utilizing our gp96 platform to generate vaccines against SIV/HIV, malaria, zika and other infectious diseases. These trials have demonstrated gp96 is a powerful platform with antiviral activity in the lungs, as evidenced by a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models.

This News Is Huge

As we work to push back the COVID-19 pandemic, there are several weapons that we need. At the top of this list is an effective vaccine.

While several companies are working on vaccine development, development is only one piece of a very complex puzzle. Manufacturing is overwhelmingly important, and Heat Biologics knows it.

With the company working to make sure that upon completion of development, it is capable of manufacturing large quantities of its COVID-19 vaccine, the stock is becoming more and more attractive.

Ultimately, there’s good reason to be excited about HTBX stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.